Omid Salaami1, Chia-Ling Kuo2, Matthew T Drake3, George A Kuchel2, James L Kirkland4, Robert J Pignolo5. 1. Department of Geriatric Medicine, Duke University, Durham, NC. 2. UConn Center on Aging, University of Connecticut School of Medicine, Farmington, CT. 3. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, MN; Department of Medicine and Kogod Center on Aging, Mayo Clinic, Rochester, MN. 4. Department of Medicine and Kogod Center on Aging, Mayo Clinic, Rochester, MN. 5. Department of Medicine and Kogod Center on Aging, Mayo Clinic, Rochester, MN; Division of Geriatric Medicine and Gerontology, Mayo Clinic, Rochester, MN. Electronic address: pignolo.robert@mayo.edu.
Abstract
OBJECTIVE: To evaluate the antidiabetic effects of the senolytic agent dasatinib in older patients with type 2 diabetes mellitus. METHODS: This retrospective cohort study included enterprise-wide Mayo Clinic patients using Informatics for Integrating Biology at the Bedside from January 1994 through December 2019. The antidiabetic outcomes (change in hemoglobin A1c value, serum glucose concentration, and diabetic medications) after 1 year of a strongly senolytic tyrosine kinase inhibitor, dasatinib (n=16), was compared with a weakly senolytic tyrosine kinase inhibitor, imatinib (n=32). RESULTS: Relative to imatinib, patients treated with dasatinib had a mean reduction of 43.7 mg/dL (P=.005) in serum glucose concentration (to convert glucose values to mmol/L, multiply by 0.0555) and required 28.8 fewer total daily insulin units (P=.08) in the setting of a 4.8-kg relative weight loss (5.3% of total body weight; P=.045). Linear regression analysis suggests that the relative difference in weight accounts for 8.4 mg/dL of the 43.7 mg/dL blood glucose value decrease, or 19.2%. Relative to imatinib, patients treated with dasatinib had a mean 0.80 absolute point (P=.05) reduction in hemoglobin A1c and required 18.2 fewer total daily insulin units (P=.16) in the setting of a 5.9-kg relative weight loss (6.3% of total body weight; P=.06). CONCLUSION: Dasatinib may have antidiabetic effects comparable to contemporary diabetic treatments and may be considered for use as a novel diabetic therapy. Future studies are needed to determine whether these results are translatable to patients with type 2 diabetes mellitus without underlying malignant diseases and to determine whether the antidiabetic effects of dasatinib are due to its senolytic properties.
OBJECTIVE: To evaluate the antidiabetic effects of the senolytic agent dasatinib in older patients with type 2 diabetes mellitus. METHODS: This retrospective cohort study included enterprise-wide Mayo Clinic patients using Informatics for Integrating Biology at the Bedside from January 1994 through December 2019. The antidiabetic outcomes (change in hemoglobin A1c value, serum glucose concentration, and diabetic medications) after 1 year of a strongly senolytic tyrosine kinase inhibitor, dasatinib (n=16), was compared with a weakly senolytic tyrosine kinase inhibitor, imatinib (n=32). RESULTS: Relative to imatinib, patients treated with dasatinib had a mean reduction of 43.7 mg/dL (P=.005) in serum glucose concentration (to convert glucose values to mmol/L, multiply by 0.0555) and required 28.8 fewer total daily insulin units (P=.08) in the setting of a 4.8-kg relative weight loss (5.3% of total body weight; P=.045). Linear regression analysis suggests that the relative difference in weight accounts for 8.4 mg/dL of the 43.7 mg/dL blood glucose value decrease, or 19.2%. Relative to imatinib, patients treated with dasatinib had a mean 0.80 absolute point (P=.05) reduction in hemoglobin A1c and required 18.2 fewer total daily insulin units (P=.16) in the setting of a 5.9-kg relative weight loss (6.3% of total body weight; P=.06). CONCLUSION: Dasatinib may have antidiabetic effects comparable to contemporary diabetic treatments and may be considered for use as a novel diabetic therapy. Future studies are needed to determine whether these results are translatable to patients with type 2 diabetes mellitus without underlying malignant diseases and to determine whether the antidiabetic effects of dasatinib are due to its senolytic properties.
Authors: Yi Zhu; Tamara Tchkonia; Tamar Pirtskhalava; Adam C Gower; Husheng Ding; Nino Giorgadze; Allyson K Palmer; Yuji Ikeno; Gene B Hubbard; Marc Lenburg; Steven P O'Hara; Nicholas F LaRusso; Jordan D Miller; Carolyn M Roos; Grace C Verzosa; Nathan K LeBrasseur; Jonathan D Wren; Joshua N Farr; Sundeep Khosla; Michael B Stout; Sara J McGowan; Heike Fuhrmann-Stroissnigg; Aditi U Gurkar; Jing Zhao; Debora Colangelo; Akaitz Dorronsoro; Yuan Yuan Ling; Amira S Barghouthy; Diana C Navarro; Tokio Sano; Paul D Robbins; Laura J Niedernhofer; James L Kirkland Journal: Aging Cell Date: 2015-04-22 Impact factor: 9.304
Authors: Allyson K Palmer; Tamara Tchkonia; Nathan K LeBrasseur; Eduardo N Chini; Ming Xu; James L Kirkland Journal: Diabetes Date: 2015-07 Impact factor: 9.461
Authors: Allyson K Palmer; Ming Xu; Yi Zhu; Tamar Pirtskhalava; Megan M Weivoda; Christine M Hachfeld; Larissa G Prata; Theo H van Dijk; Esther Verkade; Grace Casaclang-Verzosa; Kurt O Johnson; Hajrunisa Cubro; Ewald J Doornebal; Mikolaj Ogrodnik; Diana Jurk; Michael D Jensen; Eduardo N Chini; Jordan D Miller; Aleksey Matveyenko; Michael B Stout; Marissa J Schafer; Thomas A White; LaTonya J Hickson; Marco Demaria; Vesna Garovic; Joseph Grande; Edgar A Arriaga; Folkert Kuipers; Thomas von Zglinicki; Nathan K LeBrasseur; Judith Campisi; Tamar Tchkonia; James L Kirkland Journal: Aging Cell Date: 2019-03-25 Impact factor: 11.005
Authors: Matthew J Yousefzadeh; Yi Zhu; Sara J McGowan; Luise Angelini; Heike Fuhrmann-Stroissnigg; Ming Xu; Yuan Yuan Ling; Kendra I Melos; Tamar Pirtskhalava; Christina L Inman; Collin McGuckian; Erin A Wade; Jonathon I Kato; Diego Grassi; Mark Wentworth; Christin E Burd; Edgar A Arriaga; Warren L Ladiges; Tamara Tchkonia; James L Kirkland; Paul D Robbins; Laura J Niedernhofer Journal: EBioMedicine Date: 2018-09-29 Impact factor: 8.143